Gastroenterology

IBS care is evolving with personalized, multimodal strategies, but gaps in access, education, and real-world outcomes continue to impact patients’ lives

AbbVie submitted an FDA application for risankizumab subcutaneous induction in Crohn's disease based on phase 3 AFFIRM data.

If approved, the novel corticosteroid therapy would be the first and only FDA-approved hydrocortisone acetate suppository.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Sarah Enslin, PA-C, and Jennifer Geremia, PA-C, discuss the diagnosis and management of EPI, reflecting on ongoing challenges in the field.

Positive 12-week induction data from Part A of the phase 2 trial highlight the potential best-in-class safety and efficacy of SPY001, a novel anti-α4β7 therapy.

Rezaie explains how IBS care has shifted from symptom-based treatment to targeted, mechanism-driven strategies.

New long-term data link antidepressant use in IBS to higher mortality risk. Rezaie explains key findings and clinical implications.

Q1 2026 GI updates include advances in IBD and IBS therapies, long-term data, and new insights into access challenges for younger patients.

Catch up on new IBD drug trial data, updated HE guidelines from the American College of Gastroenterology, and more.

Gerlud explains unmet needs in EPI, including underdiagnosed patient populations, and the intense pill burdens patients face.

Gerlud explains why exocrine pancreatic insufficiency is often missed, even in high-risk patients.

ACG's 24 new HE recommendations tackle ammonia testing, lactulose titration, protein intake, and transplant criteria for cirrhosis patients.

Kichler notes that EPI is frequently overlooked in patients with symptoms resembling IBD or celiac disease and offers key insights on diagnosis and management.

McDonald discusses new trial data suggesting an initial vancomycin taper may reduce early recurrence of C difficile infection.

Long discusses AFFIRM data showing strong clinical and endoscopic outcomes with SC risankizumab (Skyrizi) induction in Crohn’s disease.

Williams explains colorectal cancer screening options, persistent barriers to uptake, and strategies to improve screening rates.

Stay updated with the latest healthcare breakthroughs, FDA actions, and new trial data, in this week’s essential news roundup.

Catch up on durability data and real-world insight from trials across inflammatory bowel disease and short bowel syndrome.

Risankizumab achieved superiority for the co-primary and ranked secondary endpoints at week 12 for SC injection versus placebo.

David Rubin, MD, discusses rapid advances in IBD care, new therapies, multidisciplinary models, and the push toward precision GI medicine.

4-year LUCENT data show mirikizumab reduces UC-related hospitalizations and surgeries, supporting durable remission and potential disease modification.

Hurtado-Lorenzo discusses trial data showing time-restricted feeding in Crohn’s disease results in weight loss, symptom improvement, and microbiome changes.

SEQUENCE trial data highlight sustained 3-year clinical and endoscopic remission with risankizumab in anti-TNF–exposed Crohn’s patients.